Genfit - ADR

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Genfit SA (NASDAQ: GNFT) shares shot up 150% in the after-hours trading today. What Happened: The France-based late-stage biopharmaceutical company said in the after-hours Tuesday that positive results from the Phase 2 trial evaluating elafibranor in patients with Primary Biliary Cholangitis have been published.

Why Genfit Shares Soared 150% Today

Lille, France; Cambridge, MA; February 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that the positive results from the Phase 2 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC) with incomplete response to ursodeoxycholic acid (UDCA) have been published in the Journal of Hepatology .

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Lille, France; Cambridge, MA; January 28, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that  Pascal Caisey, Chief Commercial Officer, and Philippe Motté Chief Regulatory and Quality Officer have joined the Executive Committee.

GENFIT Announces Two Key Appointments to the Executive Committee

Lille, France; Cambridge, MA; January 27, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announced that technical corrections were made to the voting results of the holders of the convertible bonds issued by the Company on October 16, 2017 (the “OCEANEs”) at the Bondholders Meeting which took place on January 25, 2021 (the “Bondholders Meeting”). These corrections have no impact on the fact that all of the resolutions by the Bondholders Meeting were approved, and are the result of corrections made by BNP Paribas Securities Services, the external provider in charge of centralizing the Bondholders Meeting votes. They are not the result of any action or responsibility of the Company.

GENFIT: Technical Corrections to the Results of the January 25, 2021 Bondholders Meeting with No Impact on Resolutions' Approval

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #GNFT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA and Encourages Investors with Losses of $100,000 to Contact the Firm

Lille, France; Cambridge, MA; January 13, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announces the publication in the January 13, 2021 French Bulletin des Annonces Légales Obligatoires of its convening notice for the shareholders' extraordinary general meeting to be held on second notice on Monday, January  25, 2021, at 2:30 p.m. (Paris time) (the “Extraordinary General Meeting”) and informs holders of its bonds convertible into new shares and/or exchangeable for existing shares issued by the Company on October 16, 2017 (the “OCEANEs”) of certain changes in certain of the participation and organization procedures for the meeting of the holders of the OCEANEs of January 25, 2021, at 5:30 p.m. (Paris time) (the “Bondholders' Meeting”).

GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders' Meeting of January 25, 2021

Lille, France; Cambridge, MA; January 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today informs its shareholders of certain changes in certain of the participation and organization procedures for the extraordinary general meeting of January 13, 2021 (the “Extraordinary General Meeting”), following the publication of decree n° 2020-1614 of December 18, 2020 extending and modifying decree n° 2020-418 of April 10, 2020 specifying the procedures for holding meetings behind closed doors (the “Decree”). Consequently, the procedures for participation in the Extraordinary General Meeting indicated in this press release (proxy representation, written questions, composition of the Committee and broadcast details) supplement those set out in the notice (avis) published in the Bulletins des Annonces Légales Obligatoires, no. 146 dated December 7, 2020.

GENFIT Informs its Shareholders of Certain Procedures for the Extraordinary General Meeting of January 13, 2021

Lille, France; Cambridge, MA; January 6, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that it will be presenting at the following upcoming investor conferences and host a Primary Biliary Cholangitis (PBC) KOL event for the financial community.

GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $GNFT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Genfit SA American Depository Shares (NASDAQ: GNFT) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Act of 1933 pursuant to the Company's initial public offering in the U.S., conducted on March 27, 2019 (the "IPO"). Genfit is a biopharmaceutical company that develops therapeutic and diagnostic solutions fo

Shareholder Alert: Robbins LLP Announces That Genfit SA (GNFT) is Being Sued for Misleading Shareholders

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #classaction--The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A.

BENSALEM, Pa.--(BUSINESS WIRE)---- $GNFT #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A.

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

Lille (France), Cambridge (Massachusetts, United States), December 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that it has signed bond repurchase agreements with holders of its convertible bonds maturing in October 2022 (the “OCEANEs”).

GENFIT announces the successful completion of a key milestone in the partial buyback and amendment of its OCEANEs

Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that:

GENFIT announces satisfactory preliminary results of its OCEANEs' partial buyback offer

Lille (France), Cambridge (Massachusetts, United States), November 23, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the final terms of the partial buyback of its convertible bonds maturing in October 2022 (“2022 OCEANEs” or “OCEANEs”) and the proposed amendment of the existing terms of the 2022 OCEANEs.

GENFIT Announces Final Terms For Proposed Renegotiation of 2022 OCEANE Convertible Bonds

Lille (France), Cambridge (Massachusetts, United States), November 16, 2020 – GENFIT (Nasdaq and Euronext: GNFT a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced that data on NIS4™ technology and the complete RESOLVE-IT Phase 3 NASH clinical trial were among those highlighted in five posters at The Liver Meeting Digital Experience™ (TLMdX), the annual scientific congress of the American Association for the Study of Liver Diseases (AASLD), that was held virtually  from November 13 to November 16, 2020.

GENFIT: New Data Presented at AASLD The Liver Meeting Digital Experience™

GENFIT: Third Quarter 2020 Financial Information and Launch of Renegotiation of Convertible Bond

GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript

GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy

Labcorp Holdings Inc

Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH).

Genfit and Lab Corp Partner Up For NASH Liver Test

GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

Lille, France; Cambridge, M.A.; September 24, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the first patient first visit for ELATIVE, the global, pivotal, Phase 3 study evaluating elafibranor in Primary Biliary Cholangitis (PBC).

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Lille, France; Cambridge, M.A.; September 22, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, will announce its first half-year 2020 financial results and new corporate strategy following market close on Wednesday, September 30, 2020.

GENFIT To Announce First Half-Year 2020 Financial Results and New Corporate Strategy on September 30, 2020

Lille, France; Cambridge, M.A.; August 26, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced two oral presentations on new non-alcoholic steatohepatitis (NASH) data, at the Digital International Liver Congress™ 2020, the 55th Annual Meeting of the European Association for the Study of the Liver (EASL), to be held virtually August 27-29, 2020.

GENFIT Announces Two Oral Presentations at the Digital International Liver Congress™ 2020

Lille (France), Cambridge (Massachusetts, United States), August 05, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced that pivotal data describing the derivation and validation of NIS4™ has been accepted for publication by   The Lancet Gastroenterology & Hepatology  . NIS4™ is GENFIT’s novel non-invasive, blood-based diagnostic technology, developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F> 2), also referred to as at-risk NASH in the published study.  

News for Genfit - ADR Stock (GNFT)